Metabolic syndrome: a clinical and molecular perspective.

By D. Moller, K. Kaufman. Annual Review of Medicine, 2005

669 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Epidemiology

View Paper: https://www.semanticscholar.org/paper/cee94cd6397b51922c2ec7974c9f41bccc21c860

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. William L. Holland

In Epidemiology

1. D. Moller
2. William L. Holland

Citations in the corpus

• The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. (2013, background): “Most patients with diabetes have other features of the metabolic syndrome—defined by the presence of three or more of the following signs and symptoms: glucose intolerance, abdominal obesity, hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C) levels, and hypertension (Moller and ”
• Association between insulin resistance and the development of cardiovascular disease (2018, background): “In this vein, an insulin resistant state is defined as the impairment of glucose uptake in muscle and an increased gluconeogenesis by the liver resulting in hyperglycemia, both in fasting and postprandial states [35].”